Treatment-Resistant Schizophrenia

被引：135
作者：
Elkis, Helio [1 ]
Buckley, Peter F. [2 ]
机构：
[1] Inst Psiquiatria HC FMUSP, Rua Ovidio Pires de Campos 785, BR-05403010 Sao Paulo, SP, Brazil
[2] Med Coll Georgia, Augusta, GA 30912 USA
来源：
PSYCHIATRIC CLINICS OF NORTH AMERICA | 2016年 / 39卷 / 02期
基金：
巴西圣保罗研究基金会;
关键词：
Schizophrenia; Treatment; Resistance; COGNITIVE-BEHAVIORAL THERAPY; HIGH-DOSE OLANZAPINE; ANTIPSYCHOTIC TREATMENT RESISTANCE; PLASMA CLOZAPINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; DOPAMINE SYNTHESIS CAPACITY; SYNDROME SCALE PANSS; DOUBLE-BLIND; TREATMENT RESPONSE; CLINICAL-RESPONSE;
D O I：
10.1016/j.psc.2016.01.006
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy. In terms of the underlying mechanisms of the development of TRS, progress has been made for the elucidation of the neurochemical mechanisms. Structural neuroimaging studies have shown that patients with TRS have significant reduction of the prefrontal cortex volume when compared with non- TRS. This article updates and enhances our previous review with new evidence mainly derived from new studies, clinical trials, systematic reviews, and meta-analyses.
引用
收藏
页码：239 / +
页数：28
相关论文
共 195 条
[61]  
Freitas RR, 2015, SCHIZOPHRENIA BULL, V41, pS103
[62]   PREFRONTAL SULCAL PROMINENCE IS INVERSELY RELATED TO RESPONSE TO CLOZAPINE IN SCHIZOPHRENIA [J].
FRIEDMAN, L ;
KNUTSON, L ;
SHURELL, M ;
MELTZER, HY .
BIOLOGICAL PSYCHIATRY, 1991, 29 (09) :865-877
[63]  
FRIEDMAN L, 1992, J PSYCHIATR NEUROSCI, V17, P42
[64]   Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [J].
Geddes, J ;
Freemantle, N ;
Harrison, P ;
Bebbington, P .
BRITISH MEDICAL JOURNAL, 2000, 321 (7273) :1371-1376
[65]   Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? [J].
Green, MF ;
Kern, RS ;
Braff, DL ;
Mintz, J .
SCHIZOPHRENIA BULLETIN, 2000, 26 (01) :119-136
[66]  
Guy W., 1976, CGI clinical global impressions
[67]   Recovery from psychotic illness:: a 15-and 25-year international follow-up study [J].
Harrison, G ;
Hopper, K ;
Craig, T ;
Laska, E ;
Siegel, C ;
Wanderling, J ;
Dube, KC ;
Ganev, K ;
Giel, R ;
An der Heiden, W ;
Holmberg, SK ;
Janca, A ;
Lee, PWH ;
León, CA ;
Malhotra, S ;
Marsella, AJ ;
Nakane, Y ;
Sartorius, N ;
Shen, Y ;
Skoda, C ;
Thara, R ;
Tsirkin, SJ ;
Varma, VK ;
Walsh, D ;
Wiersma, D .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 :506-517
[68]   World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance [J].
Hasan, Alkomiet ;
Falkai, Peter ;
Wobrock, Thomas ;
Lieberman, Jeffrey ;
Glenthoj, Birte ;
Gattaz, Wagner F. ;
Thibaut, Florence ;
Moeller, Hans-Juergen .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2012, 13 (05) :318-378
[69]  
HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409
[70]   Suicidal risk during treatment with clozapine: a meta-analysis [J].
Hennen, J ;
Baldessarini, RJ .
SCHIZOPHRENIA RESEARCH, 2005, 73 (2-3) :139-145
234567891011